Fundraising Masterclass: Health tech traction w Marko Kuisma

Marko Kuisma, Partner at Innovestor Life Sciences, joins us to unpack exactly that. He'll walk through what health tech and life sciences investors look for at each stage; from pre-seed to Series A. Expect a practical breakdown of: Regulatory milestones that function as proof points, and which ones actually matter to investors Clinical validation what stage of evidence de-risks a deal enough to unlock funding Non-dilutive funding (grants, contracts) as a signal of credibility, not just capital How "traction" evolves across rounds:What's enough at pre-seed vs. what Series A investors expect to see. If you're building in health tech or life sciences and wondering what to show when revenue isn't the story yet, this session is built for you.